🇺🇸 Serotonin-norepinephrine reuptake inhibitor in United States

7 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Decreased Appetite — 2 reports (28.57%)
  2. Acute Psychosis — 1 report (14.29%)
  3. Drug Ineffective For Unapproved Indication — 1 report (14.29%)
  4. Insomnia — 1 report (14.29%)
  5. Therapeutic Response Unexpected — 1 report (14.29%)
  6. Weight Decreased — 1 report (14.29%)

Source database →

Serotonin-norepinephrine reuptake inhibitor in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Serotonin-norepinephrine reuptake inhibitor approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Serotonin-norepinephrine reuptake inhibitor in United States?

University of Washington is the originator. The local marketing authorisation holder may differ — check the official source linked above.